Jazz Gets Intermediate Victory in Patent Fight, Likely to Maintain Xyrem Exclusivity: Analyst 

Drug Industry Daily
A A
Jazz Pharmaceuticals received some positive, if minor, news in its legal battle to maintain exclusivity for its narcolepsy drug Xyrem this week when a district court denied generic-drug maker Roxane Laboratories’ request to submit additional evidence showing that Jazz’s patents are invalid.

To View This Article:

Login

Subscribe To Drug Industry Daily